Login to Your Account



HAVE YOUR CLOT AND BUST IT, TOO

Platelet activation blocker affects clotting more than bleeding

By Anette Breindl
Senior Science Editor

Friday, January 6, 2017

Blocking platelet aggregation by inhibiting the protease-activated receptor PAR4 prevented the formation of harmful blood clots, while having less of an effect on blood clots that repaired injury. The results, which were published in the Jan. 4, 2017, issue of Science Translational Medicine, "validate PAR4 as an antithrombotic target with the potential for a favorable safety/efficacy ratio," Michael Burgess, head of cardiovascular, fibrosis, immunoscience and GDD development at Bristol-Myers Squibb Co. (BMS), told BioWorld Today.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription